EUCTR2007-003233-16-BE进行中（未招募）不适用
A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects who have completed the 26 weeks treatment period of the TH9507-CTR-1011 study.
- •2. Signed informed consent before any trial-related activities.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Fasting blood glucose >8.33 mmol/L (150 mg/dL) at the end of the TH9507-CTR-1011 study.
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat AccumulatioHIV-associated lipodystrophyMedDRA version: 8.1Level: LLTClassification code 10024608Term: LipodystrophyEUCTR2006-005444-88-BETheratechnologies Inc.400
进行中（未招募）
1 期
A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat AccumulatioHIV-associated lipodystrophyMedDRA version: 8.1 Level: LLT Classification code 10024608 Term: LipodystrophyEUCTR2006-005444-88-GBTheratechnologies Inc.400
进行中（未招募）
不适用
A Multicenter, Double-blind, Randomized, Placebo-Controlled Study to Measure the Effect of FX06 (a fibrin derived peptide Bß15-42) on Ischemia-Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention (PCI): The F.I.R.E.” Study - The F.I.R.E. StudyEUCTR2006-000619-51-NLFibrex Medical Research & Development GmbH120
进行中（未招募）
不适用
A Multicenter, Double-blind, Randomized, Placebo-Controlled Study to Measure the Effect of FX06 (a fibrin derived peptide Bß15-42) on Ischemia-Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention (PCI): The F.I.R.E.” Study - The F.I.R.E. StudyEUCTR2006-000619-51-LTFibrex Medical Research & Development GmbH220
进行中（未招募）
不适用
A Multicenter, Double-blind, Randomized, Placebo-Controlled Study to Measure the Effect of FX06 (a fibrin-derived peptide Bß15-42) on Ischemia-Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention (PCI): The F.I.R.E.” Study - FIREPatients with acute myocardial infartion (AMI) for Percutaneous Coronary Intervention (PCI).MedDRA version: 8.0Level: LLTClassification code 10000891EUCTR2006-000619-51-BEFibrex Medical Research & Development GmbH140